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Abstract: Basal cell carcinoma (BCC) of the skin is the most common type of cancer and 
accounts for up to 40% of all cancers in the US, with a growing incidence rate over recent decades 
in all developed countries. Surgery is curative for most patients, although it leaves unaesthetic 
scars, but those that develop locally advanced or metastatic BCC require different therapeutic 
approaches. Furthermore, patients with BCC present a high risk of developing additional 
tumors. The increasing economic burden and the morbidity of BCC render primary interest in 
the development of targeted treatments for this disease. Among the molecular signals involved 
in the development of BCC, the critical role of the morphogenetic Hedgehog (Hh) pathway has 
become evident. This pathway is found altered and activated in almost all BCCs, both sporadic 
and inherited. Given the centrality of the Hh pathway in the pathophysiology of BCC, the 
primary efforts to identify molecular targets for the topical or systemic treatment of this cancer 
have focused on the Hh components. Several Hh inhibitors have been so far identified – from 
the first identified natural cyclopamine to the recently Food and Drug Administration-approved 
synthetic vismodegib – most of which target the Hh receptor Smoothened (either its function 
or its translocation to the primary cilium). Other molecules await further characterization 
(bisamide compounds), while drugs currently approved for other diseases such as itraconazole 
(an antimicotic agent) and vitamin D3 have been tested on BCC with encouraging results. The 
outcomes of the numerous ongoing clinical trials are expected to expand the field in the very 
near future. Further research is needed to obtain drugs targeting downstream components of 
the Hh pathway (eg, Gli) or to exploit combinatorial therapies (eg, with phosphatidylinositol 
3-kinase inhibitors or retinoids) in order to overcome potential drug resistance.
Keywords: BCC, Hedgehog, vismodegib, Smo inhibitors, Gli antagonists, retinoids, 
itraconazole, vitamin D3
Introduction
Basal cell carcinoma (BCC) of the skin is the most common type of cancer and 
accounts for up to 40% of all cancers in the US.1 BCC, together with squamous cell 
carcinoma, is grouped into the so-called nonmelanoma skin cancers which present 
cells with keratinocytic morphology.2
BCC is characterized by cells that morphologically resemble the undifferentiated 
cells that constitute the basal layer of the epidermis or hair follicle, but may 
present different growth patterns (infiltrating, superficial, nodular, sclerosing, and 
fibroepithelial), indicating that the cell of origin may be a stem or progenitor cell.3,4
BCC tumors are generally curable and thus frequently not reported in cancer 
registries, making it difficult to estimate the real incidence of the disease. A report 
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estimated BCC occurrence in the US of more than 2 million 
cases in 2006, with some patients having multiple diagnoses.5 
In 95% of cases, the diagnosis is made in 40–79 year olds 
mainly of Caucasian origin, with a 30% higher incidence in 
men than in women.6
Exposure to sunlight (ultraviolet rays) is the most important 
risk factor (in most cases the lesion is in a region of the body 
exposed to the sun); other well known risk factors are exposure 
to ionizing radiations, arsenic, and immunosuppressive 
conditions as well as genetic syndromes such as the basal cell 
nevus syndrome (BCNS) or Gorlin syndrome.3,6
Despite its very high frequency, this tumor rarely leads 
to death, partly because of the remarkable progress made in 
the field of diagnosis and treatment, but also for the fact that 
it rarely metastasizes. However, since BCC often infiltrates 
the skin locally and aggressively and involves disfiguring 
surgical resection, it is considered a malignant tumor. It is 
important to observe that metastatic patients, although very 
rare (0.003%–0.5% of cases), often present a poor prognosis 
with mean survival ranging from 8 months to 3.6 years.7
A recent systematic review of the published data suggests 
that the incidence rate of BCC has grown in recent decades 
in developed countries, probably because of the now 
widespread practice of sunbathing.8 The increasing relevance 
of the economic burden and the morbidity of BCC render 
primary interest in a better understanding of the molecular 
biology of BCC and the development of targeted treatments 
for this disease.9
Current therapeutic approaches
Surgery is still the elective choice for most BCCs, especially 
the early-stage and low-risk ones, which can be removed 
by surgical excision, electrodessication, curettage (tissue 
destruction by electric current and removal by scraping with 
a curette), or cryosurgery (tissue destruction by freezing). 
In the presence of specific risk factors, Mohs micrographic 
surgery is the elective treatment.10 Surgery is curative for 
most patients, although it leaves unaesthetic scars, but those 
that develop locally advanced or metastatic BCC require 
different therapeutic approaches.10
Furthermore, patients with BCC present a high risk 
of developing additional tumors (up to 44% incidence 
within 3 years from the first tumor),11 and some sort of 
preventive treatment on these patients may avoid the need 
for performing surgical resection again (which often causes 
disfigurement).
Until last year, the most common nonsurgical therapies 
for BCC involved radiotherapy, photodynamic therapy, or 
the topical administration of imiquimod and 5-fluorouracil, 
although the cure rates were low.10,12 Treatment of BCC 
with other agents, such as tazarotene, glycoalkaloid (BEC5) 
cream, cidofovir, and calcium dobesilate have also been 
reported,13 although many of them did not look really promis-
ing, prompting the search for more targeted and preventive 
therapies.
Development of new BCC  
anticancer drugs: targeting  
the Hedgehog (Hh) pathway
Among the molecular signals involved in the development 
of BCC, the critical role of the morphogenetic Hh pathway 
has become evident.14,15 This pathway is found altered and 
activated in almost all BCCs, both sporadic and inherited,16,17 
as well as in most tumor stem cells and in other tumors such 
as medulloblastoma and rhabdomyosarcoma.17–19
The Hh pathway is a key regulator of embryonic pattern-
ing and cell fate determination.20 It plays a critical role in the 
development of various tissues in mammals as a morphoge-
netic, mitogen and differentiation factor.21–26
The Hh pathway (Figure 1) is activated by a family 
of secreted ligands (Sonic, Desert, and Indian Hh). These 
ligands are synthesized as pro-proteins, which undergo 
several posttranslational modif ications: autocatalytic 
cleavage to generate the active n-terminal fragment 
followed by linking to a cholesterol molecule and to a 
palmitic acid.27,28 These modifications are essential for Hh 
proteins to cross the membrane bilayers and to interact 
physically with lipoproteins, allowing diffusion of the 
ligand towards the nearby or distant target cells where Hh 
interacts with the transmembrane receptor Patched (Ptch).27,28 
This bond prevents the inhibition mediated by Ptch on the 
coreceptor Smoothened (Smo), allowing Smo derepression 
and translocation in the primary cilium and leading to the 
downstream activation of the Gli family of transcription 
factors (Gli1-3).14,15,29
Recent studies suggest that Smo signaling activity 
can be modulated positively by natural and synthetic 
small molecules, including oxysterols (oxidized forms of 
cholesterol),30 and Ptch regulates Smo by pumping away 
oxysterols from Smo.31 Indeed, Ptch receptor contains a sterol 
sensing domain that has been linked to the regulation of the 
vesicular trafficking of Smo.32
Specific oxysterols can drive differentiation of osteogenic 
cells in culture and in animals.33,34 The most potent activator so 
far identified is 20(S)-hydroxycholesterol, which binds Smo 
and leads to its accumulation in the primary cilium.35,36
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Once activated, Gli transcription factors translocate into 
the nucleus and promote the expression of target genes. 
Recently, it has been demonstrated that Gli transcriptional 
activity and nuclear localization are also modulated negatively 
by acetylation. In fact, deacetylation by histone deacetylases 
is required for full transcriptional activity.37 Gli proteins 
promote the expression of genes involved in the control 
of the most important cell functions such as proliferation, 
differentiation, and survival. Dysregulated Hh activity is for 
this reason frequently implicated in cancerogenesis.38
The first hint of Hh involvement in BCC came from the 
analysis of the inherited forms of BCC, associated with BCNS, 
an autosomal dominant disorder characterized by skeletal 
abnormalities, endocrine disorders, and predisposition to 
the development of BCC and medulloblastoma,39 which 
was found to be caused by a germline mutation of the Hh 
receptor Ptch1.40,41
Like the hereditary form of BCC, the most common 
genetic alterations found in sporadic BCC are mutations 
of the receptor Ptch1 (inactivating mutations or loss of 
heterozygosity),42–44 which prevent its inhibition on Smo 
receptor – allowing the activation of downstream signals even 
in the absence of ligands.42 Less frequent genetic alterations 
are gain of function mutations on Smo or mutations of the Hh 
inhibitor suppressor of fused (SuFu).43,45–47 Similarly, mouse 
models overexpressing Sonic Hh (Shh) ligand in the skin 
present BCC formation,48 although human BCCs generally 
do not present this alteration.
Given the centrality of the Hh pathway in the pathophysiology 
of BCC, the primary efforts to identify molecular targets for 
the topical or systemic treatment of this cancer have focused 
on the Hh components (Figure 1; Table 1).
Development of Smo inhibitors
Cyclopamine
The first Hh inhibitor that has been identified is cyclopamine, 
a natural molecule found in Veratrum californicum (corn 
lilies) and recognized as a teratogen in cattle since the 
second half of the 1900s.49 The suppression of the Hh 
pathway through inhibition of Smo was later identified as 
the mechanism of the teratogenic malformation induced by 
cyclopamine.50,51
The feasibility of cyclopamine use in therapy was 
suggested by its Hh inhibition on tumor cells.52,53 Cyclopamine 
(and its more effective derivative KAAD-cyclopamine) 
was successfully used topically on BCC, although with an 
inconvenient treatment schedule,54 verifying the rationale 
for the use of this class of molecules for cancer treatment. 
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Itraconazole
HPI 2-4
PI3K inhibitors
Retinoids
Phenyl quinaz
EGFR
EGFR
Ras/Raf
PI3K
MEK
ERK
PKB/akt
GANT58/61HPI1TSA Ac
KCASH
SuFu
Hdac
Gli
Gli
Gli
Pathway
inhibitors
Vismodegib
Erismodegib/LDE225
LEQ506
Saridegib/IPI-926
PF-04449913
Bis-amides
Robotk
5E1ab
Oxystesterol
Smo
Ptch
P ChHh
VitD3
TAK-441
Figure 1 The Hh pathway critical components which could be targeted by potential antibasal cell carcinoma drugs. 
Notes: The mechanism of action of each single drug is explained in the text. The question mark indicates a so far undetermined mechanism. The EGFR and PI3K pathways 
are also sketched, given their potential contribution to Hh pathway tumorigenic activity.
Abbreviations: Ac, acetyl group; Ch, cholesterol; EGFR, epidermal growth factor receptor; ERK, extracellular signal-related kinase; GANT, Gli antagonist; Hdac, histone 
deacetylase; Hh, Hedgehog; HPI, Hedgehog pathway inhibitor; KCASH, KCTD (Potassium Channel Tetramerization Domain) containing cullin3 adaptor suppressor of 
hedgehog; MEK, mitogen-activated protein kinase kinase; P, palmitate; PI3K, phosphatidylinositol 3-kinase; PKB/akt, protein kinase B; Ptch, Patched; Quinaz, quinazolines; 
Robotk, robotnikinin; Smo, Smoothened; SuFu, suppressor of fused; TSA, trichostatin A; VitD3, Vitamine D3.
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The availability of more potent and bioavailable derivatives 
(see below) has currently halted cyclopamine clinical 
development.
Vismodegib (GDC-0449)
Vismodegib (GDC-0449) belongs to the second class of Hh 
inhibitors, molecules capable of binding the target with higher 
affinity.55,56 Vismodegib was identified in a high-throughput 
screening of molecules optimized by means of targeted 
chemical modifications.57 In 2009, Von Hoff et al published 
the promising results of a Phase I clinical trial of patients 
with locally advanced or metastatic BCC: of the 33 enrolled 
patients, 18 showed response to treatment (two complete 
and the other 16 partial) and the remaining 15 showed stable 
disease (n = 11) or progression (n = 4).58 Following this 
trial, a 150 mg/day trial with 104 patients showed a 30% 
response rate per metastatic BCC and a 43% rate per locally 
advanced BCC. Adverse events have proved tolerable.59 
Given these results, vismodegib was approved by the Food 
and Drug Administration (FDA) in January 2012 for the 
treatment of locally advanced or metastatic BCC, ie, for 
those patients for whom it is impossible to resort to surgery 
or radiotherapy.56,60
Later on during 2012, results from one more clinical trial 
were published: Tang et al administered the drug to patients 
with BCNS and demonstrated its effectiveness in reducing 
preexisting lesions (mean -65% versus -11% placebo) 
and inhibiting new lesion formation (average two versus 
29 per year).61 Histological samples taken from patients who 
received the treatment for at least 1 month showed a reduction 
of 90% in Hh activity (measured by the levels of Gli1).
Although the efficacy of the therapy was striking and led 
to quick acceptance, given its low toxicity, questions still 
remain that prompt further research in the field:
–	 First of all, despite these positive results, trials have 
indicated that after discontinuation of therapy a 
Table 1 List of the anti-Hedgehog drugs currently undergoing clinical trials
Drug Target Cancer type Phase Clinicaltrials.gov ID
Vismodegib Smo BCNS II NCT00957229
Advanced/mBCC II NCT01367665
BCC II NCT01201915
Advanced BCC II NCT00833417
Advanced/mBCC II NCT01160250
Solid tumors II NCT00959647
Colorectal II NCT00636610
Ovarian II NCT00739661
BCC II NCT01543581
Medulloblastoma I NCT01601184
Pancreatic I NCT01537107
Medulloblastoma II NCT01239316
Medulloblastoma II NCT00939484
LDE225 Smo Solid tumors I NCT00880308
NCT01208831
BCNS II NCT00961896
BCC II NCT01033019
Advanced/mBCC II NCT01327053
BCNS II NCT01350115
LEQ506 Smo Solid tumors I NCT01106508
IPI-926 Smo Solid tumors I NCT00761696
Pancreatic Ib/II NCT01130142
TAK-441 Smo Solid tumors I NCT01204073
PF-04449913 Smo Hematologic I NCT00953758
NCT01546038
Solid tumors I NCT01286467
Itraconazole Smo BCC II NCT01108094
Vitamin D3 Smo BCC III NCT01358045
Acitretin ? NMSC II NCT00020956
Tretinoin ? NMSC III NCT00007631
Tazarotene ? BCC/BCNS II NCT00489086
II NCT00783965
Abbreviations: BCC, basal cell carcinoma; BCNS, basal cell nevus syndrome; mBCC, metastatic BCC; NMSC, nonmelanoma skin cancers; Smo, smoothened; ?, currently 
undefined target.
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resumption of growth may occur.61 One hypothesis is 
that treatment is not able to kill a fraction of the cells that 
remain quiescent, and when treatment is suspended this 
population gives rise to full blown BCC.
–	 Second, a phenomenon observed during the use of 
vismodegib and potentially other inhibitors of Smo is 
drug resistance: it has been observed in medulloblastoma 
patients who have already undergone conventional 
treatments, so it may not occur with the same frequency 
in BCC patients – especially those who can be considered 
chemonaïve.62 A potential mechanism for this resistance 
is the acquisition of a Smo mutation (D473H), which 
does not allow vismodegib binding but retains its ability 
to activate the pathway.63
Other Smo inhibitors
In the last 10 years, several companies have invested in the 
search for good inhibitors of Hh, with variable results. Since 
the inhibition of Smo is the most well-known mechanism for 
interfering with the Hh pathway (as shown by the success of 
cyclopamine and vismodegib), several molecules have been 
developed for this purpose.55
Cur-61414
One of the first attempts was made by researchers at Curis 
Inc (Lexington, MA) with Cur-61414, which – although 
successful in a mouse model of BCC – failed to provide posi-
tive results in human BCC, probably because of inadequate 
penetration in the skin.64,65
NVP-LDE225, erismodegib
A more promising inhibitor is LDE225 (NVP-LDE225, 
erismodegib) a new and specific inhibitor of Smo developed 
by Novartis (Basel, Switzerland), usable both locally and 
systemically (orally).66
Skvara et al, after having shown that topical LDE225 
is able to reverse the formation of basaloid tumors in skin 
punches taken from mice Ptch1+/-, enrolled eight patients 
suffering from BCNS: a total of 27 lesions were treated 
twice a day with cream LDE225 0.75% for 4 weeks.67 
Histopathology showed a reduction in Ki-67 staining and 
a reduction in nuclear Gli1 reactivity in the lesions treated 
compared to controls; accordingly, analysis by quantitative 
polymerase chain reaction showed a reduction in the levels 
of Gli1, Gli2, and Ptch1 messenger ribonucleic acid from -2 
to -16 times in the treated lesions. Of the 13 lesions treated 
with the drug, twelve showed a response – three complete, 
understood as the disappearance of the lesions and nine partial, 
intended as a reduction of the lesions. None of the lesions 
showed evidence of complete histological clearance – Skvara 
et al suggest the existence of a subpopulation of resistant cells 
(cancer stem cells?), which may lead to tumor regrowth.4,67 
Although other conclusive data have not yet been published, 
Novartis has suspended the development of the topical 
LDE225 cream since the clinical studies did not demonstrate 
tumor clearance rates sufficient enough to support further 
clinical investigation.68
On the contrary, there are currently several ongoing 
clinical trials to test efficacy of oral administration of 
LDE225 in patients:
–	 a Phase I study of oral LDE225 in patients with advanced 
solid tumors (BCC, medulloblastoma, and others) 
(NCT00880308);
–	 a Phase II, randomized, double-blind study of efficacy 
and safety of two dose levels of LDE225 in patients with 
locally advanced or metastatic BCC (NCT01327053); 
and
–	 a Phase II trial evaluating the efficacy, safety, and 
pharmacokinetics of oral LDE225 in the treatment of 
adult patients with BCNS (NCT01350115).
A recently published paper indicates that NVP-LDE225 
monotherapy in chemonaïve tumors had little effect on 
tumor growth.69 Notably, however, NVP-LDE225 treatment 
was highly effective in preventing the recurrence of residual 
tumors following chemotherapy.69
LEQ506
Another Novartis Smo inhibitor is LEQ506,70,71 which is 
currently undergoing a Phase I clinical trial on advanced 
solid tumors: recurrent or refractory medulloblastoma or 
locally advanced or metastatic BCC (NCT01106508), for 
which results are not currently available.
IPI-926 (saridegib)
Infinity Pharmaceuticals (Cambridge, MA) has developed 
a new molecule using the cyclopamine structure as starting 
material: making a series of chemical modifications to the 
ring system of the molecule has generated IPI-926 (saridegib) 
characterized by a greater chemical stability, solubility, 
potency, selectivity, and bioavailability compared to the 
natural compound.72–74
Recently, Lee et al demonstrated that saridegib 
lengthens the life of an Hh-dependent mouse model of 
medulloblastoma.75 In this study, PtchC/C animals were treated 
for 6 weeks, with 100% survival in saridegib-treated mice 
versus 0% of controls and a reduction in clinical symptoms 
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in treated animals.75 Lee et al also suggested that saridegib 
reduces tumor-initiating capacity since they observed reduced 
tumor incidence, slower growth, and spontaneous tumor 
regression in allografts generated from previously treated 
autochthonous medulloblastomas compared with those from 
untreated donors. Lee et al did not observe the appearance 
of mutations at the level of Smo nor other resistance 
mechanisms such as amplification of Gli2 (actually, saridegib 
is active on cells transfected with a Smo mutant resistant 
to vismodegib, D473H). Despite this, a recovery in tumor 
growth accompanied by a progressive increase in the levels 
of Gli1 was observed after the 6 weeks of treatment.75
The hypothesis presented is that saridegib would seem 
to interfere with the activity of adenosine triphosphate 
binding cassette transporters (ABC) such as P-glycoprotein. 
ABC transporters are membrane proteins that use adenosine 
triphosphate for a conformational change that transport a 
variety of substrates across the cell membranes to the exterior 
and are also known for their capability as drug transporters 
out of the cells, making it difficult for the drug to reach an 
effective concentration in the cells.76,77 In fact, an increase of 
P-glycoprotein expression was observed in saridegib-treated 
tumors while administration of verapamil (an inhibitor of 
P-glycoprotein) partially restored the reduction in Gli1 
levels.75
The effect of saridegib on P-glycoprotein casts some 
doubt on the feasibility of combined therapies, given the 
fact that stronger extracellular transport means reduced 
drug efficacy, and several authors are considering ABC 
transporters as potential targets for therapy.78 Interestingly, on 
the contrary, Hhantag691 administration has been linked to 
P-glycoprotein inhibition,79 while the activity of vismodegib 
on these molecules has been evaluated as modest.80
Oral IPI-926 is cur rently undergoing clinical 
experimentation: a Phase I study on IPI-926 has been 
completed (NCT00761696) and preliminary results indicate 
that IPI-926 was well tolerated and resulted in clinical activity 
in patients with BCC.81 Further studies (a Phase Ib/II study) 
are ongoing to address the potential of a combination with 
gemcitabine in patients with more aggressive cancers (ie, 
metastatic pancreatic cancer) (NCT01130142).
Pfizer PF-04449913
Pfizer, Inc (New York, NY) has developed its own Hh 
inhibitor, PF-04449913, an orally bioavailable Smo antagonist 
and benzimidazole derivative.82 This molecule is currently being 
tested in Phase I clinical trials in hematologic malignancies 
(NCT00953758, NCT01546038) and selected advanced, 
metastatic solid tumors (NCT01286467) both as a single agent 
or in combination with standard chemotherapy agents. Recently 
presented preliminary data highlight the good tolerability of 
the drug, and early signs of efficacy have been observed in 
all hematologic diseases studied.83 Treated patients presented 
downregulation of the antiapoptotic protein B-cell lymphoma-2 
(Bcl2) and the transporter protein ABCA2.84 Although not yet 
tested on BCC, the efficacy on BCC could be assessed using a 
topical formulation since the current formulation is in tablets.
TAK-441
Millennium Pharmaceuticals, Inc (Cambridge, MA) which 
is part of Takeda Pharmaceutical Company Ltd (Osaka, 
Japan) has launched a clinical trial on the oral adminis-
tration of TAK-441, its Hh signaling pathway inhibitor 
(NCT01204073). This study involves adult patients with 
advanced nonhematological malignancies, but at the time 
of this review results were not yet available.
Bisamides
Dijkgraaf et al analyzed tumors with the Smo D473H 
mutation, resistant to vismodegib, and demonstrated an ability 
to overcome this resistance using a new type of inhibitor 
belonging to the class of bisamides.85 Confirming the validity 
of this approach, a research group from AstraZeneca (London, 
UK) recently identified another bisamide with potent Smo-
inhibiting activity and good pharmacokinetics in mice.86 Both 
molecules, although promising, need further characterization 
in vitro and/or in vivo and to be validated in clinical trials.
Itraconazole
After a screening for inhibitors of Hh using about 
2400 molecules previously tested for toxicity in humans 
or approved by the FDA, Kim et al identified itraconazole 
as a potent inhibitor of Hh.87 Itraconazole is an antifungal 
medication commonly used in clinical practice, even for 
long periods of time; it inhibits the enzyme 14-α lanosterol 
demethylase, crucial for the biosynthesis of ergosterol in 
fungi and cholesterol in mammals.9
Itraconazole gave positive results both in xenograft models 
of medulloblastoma and in the reduction of endogenous BCCs 
in murine models.87 According to Kim et al, the inhibitory 
effect on Hh by itraconazole was not mediated by its action 
on the synthesis of sterols, since the drug acted downstream 
of Ptch; on the contrary, itraconazole prevented accumulation 
of Smo in the primary cilium. Furthermore, the drug was able 
to synergize with cyclopamine, suggesting that the two drugs 
recognized two different binding sites on Smo.87
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An exploratory Phase II proof of concept clinical trial 
with itraconazole on BCC patients has been performed by 
Stanford University (NCT01108094) with positive results, 
although additional studies with larger numbers of patients 
are needed to validate these findings.88
An important aspect of itraconazole is that it has been shown 
to also inhibit angiogenesis through inhibition of vascular 
endothelial growth factor receptor trafficking and downstream 
signaling.89 Therefore, its actions may be exerted simultane-
ously on both of these important therapeutic targets.
Following the discovery of itraconazole’s potential for 
Hh inhibition, an interesting attempt has been performed to 
search for analogs of itraconazole with greater potency: 25 
itraconazole side chain analogs were synthesized obtaining 
molecules with greater inhibitory activity.90 This work also 
helped identify the distinct regions critical for anti-Hh and 
antivascular endothelial growth factor receptor activity. 
Further preclinical and clinical work is now needed to 
validate these new compounds.
Phenyl quinazolines
Another promising class of Hh inhibitors is a small family 
of phenyl quinazolinone ureas, which has been reported 
as potent modulators of Hh protein function. Preliminary 
structure–activity relationship studies of the urea substituent 
led to a nanomolar Hh antagonist (compound 7d), which 
will need further testing for specif icity, toxicity, and 
bioavalaibility.91
Vitamin D3 (calcitriol)
The literature provides wide evidence for the antitumoral 
activity of vitamin D3, showing its capabilities of blocking the 
cell cycle, inducing differentiation and apoptosis, modulating 
inflammation, and inhibiting neoangiogenesis.92,93
Vitamin D3 was shown to act both by binding to its 
nuclear receptor (VDR) and activating transcription (genomic 
effects), and by nongenomic effects, such as increasing the 
influx of calcium (Ca2+).93 A relationship between vitamin 
D3 and the Hh pathway came about by the observation 
of a Ptch-dependent secretion of provitamin D3 and by 
Smo inhibition by provitamin D3 or vitamin D3 itself.94,95 
Furthermore, mice lacking VDR present higher levels of Hh 
signaling components in the epidermis and epidermal portion 
of the hair follicles.96
The relevance of vitamin D3 and VDR in BCC 
tumorigenesis has been suggested by Kamradt et al, while 
the involvement of Hh in this mechanism was highlighted by 
an analysis of BCC formation in VDR null mice.96,97
The relevance of exploiting vitamin D3 in BCC 
chemotherapy has been demonstrated on mice overexpressing 
the Hh pathway in the skin, in which vitamin D3 leads to 
VDR activation and induces Hh repression, inhibiting BCC 
proliferation and inducing differentiation.98
Since vitamin D3 does not seem to affect basal levels 
of Gli1 in Smo-/- cells, it may control the Hh signaling 
downstream of Ptch1. Interestingly, although the promoters 
of several Hh pathway components have putative consensus 
sequences for VDR binding,93 the inhibitory effect on Hh 
seems to be independent of VDR binding by vitamin D3, 
because in VDR-/- cells the administration of calcitriol 
continues to repress Gli1 levels.98 Similar results have been 
also obtained using murine BCC cell lines.95
These data are in apparent contrast with what has been 
shown when using skin explants from VDR null mice, which 
did not present a reduction in Hh signaling following culture 
in the presence of vitamin D3,96 arguing in favor of a VDR 
requirement. One hypothesis to reconcile these different 
results is that vitamin D3 may exert both genomic (VDR 
dependent) and nongenomic (a direct action on Smo)94 
effects, which may prevail alternatively in different cellular 
and physiological settings.
To evaluate the effectiveness of topical vitamin 
D3 treatment in BCC patients following the important 
preclinical data, a Phase III clinical trial has been initiated 
(NCT01358045) to clarify the feasibility and side effects 
of such treatments. In fact, one of the reasons why such 
treatment has not been extensively tested so far in different 
tumor types is because vitamin D3 through VDR acts on 
numerous physiological systems and its activation can lead 
to negative side effects. To facilitate clinical application, 
avoiding the side effects that cause prolonged administration 
of vitamin D3, researchers have recently produced 
semisynthetic derivatives that retain the ability to repress 
Hh and do not bind to VDR, which may be tested in future 
preclinical and clinical trials.99
Blocking the Hh pathway upstream 
of Smo
Hh ligand antagonists
A few years ago, a search for small molecules acting at 
the level of the Hh ligands was performed, identifying 
robotnikinin, a macrocyclic Hh inhibitor that is able to bind 
the extracellular Shh protein and block Shh signaling.100,101
More recently, starting from the structure of robotnikinin, 
several new macrocyclic analogs with increased Hh 
inhibitory activity have been generated. Interestingly, 
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the most promising molecule (BRD-6851), in contrast to 
robotnikinin, is again a Smo antagonist.102
Another approach used to block the Hh pathway has 
been the generation of antibodies capable of binding Shh 
and to abolish its interaction with the Ptch receptor. The 
most effective and widely used antibody so far developed is 
called 5E1, which targets an epitope close to the region of 
Ptch/Shh interactions.103,104 This antibody has not so far been 
entered into any clinical trial.
Oxysterol modulation
Given the potential role of oxysterols in regulating the Hh 
pathway and more interestingly the fact that at least some 
oxysterols seem to be able to bind Smo on a site different to 
that which cyclopamine or Sag (Smo agonist) bind,36 they 
represent a potential alternative target. It is currently unclear 
how the oxysterols involved in Hh signaling regulation 
are synthesized, transported, and degraded such that their 
levels can be perturbed, but regulation of signaling sterol 
turnover might be another potential control point of the Hh 
pathway.
Blocking the Hh pathway 
downstream of Smo
Hh pathway inhibitors (HPI)
Hyman et al, in a large scale high-throughput screening for 
compounds that can inhibit Hh target gene expression induced 
by Smo and/or Sag, identified four molecules (HPI1-4) able 
to suppress Hh activity.105 They all act downstream of SuFu, 
so they are not able to directly bind Smo, but they have a 
different mechanism of action: HPI1 acts on Gli1 (both 
exogenous and endogenous), HPI2 and HPI3 act on the 
ciliary process required for Gli2 function, and HPI4 interferes 
with ciliogenesis. The capacity of these inhibitors to act 
downstream of Smo is very promising in overcoming the 
resistance against Smo inhibitors. For this reason, Chenna et al 
generated a polymer nanoparticle-encapsulated formulation 
of HPI1 (NanoHHI) that is able to arrest proliferation in 
cells which ectopically express the Smo mutant resistant to 
vismodegib (D473H).106 Furthermore, NanoHHI reduced 
growth in a medulloblastoma xenograft model and, in 
combination with gemcitabine, significantly impeded growth 
in a pancreatic cancer xenograft and in orthotopic experiments 
with hepatocellular carcinoma cells.106,107
Gli antagonists (GANT)
Almost all the inhibitors of the Hh pathway that have 
been developed so far inhibit Smo activity. However, the 
development of molecules able to act further downstream 
would allow a direct hit on the final effectors of the signaling 
pathway (ie, Gli factors) and would provide a valid alternative 
in case of drug resistance.
Unfortunately, although searches for molecules acting on 
Gli factors have been performed for some years, the successful 
evidence provided is still limited to preclinical studies.
Lauth et al in 2007 identified two GANTs (GANT58 and 
GANT61) capable of inhibiting the transcriptional activity 
of Gli1 and Gli2: GANT61 is a hexahydropyrimidine while 
GANT58 has a thiophene core with four pyridine rings.77 
Despite these structural differences, they both inhibit Gli1 
and Gli2. The two drugs showed a strong inhibitory activity 
on pancreatic cancer cells and have worked mainly in 
reducing tumor growth in a xenograft model.77
Screens of 1990 synthetic chemicals and 94 natural 
products have identif ied a few compounds that can 
antagonize Hh target gene expression induced by Gli1 or Gli2 
overexpression, including GANT58, GANT61, zerumbone, 
arcyriaflavin C, and physalin.105 How these compounds 
antagonize Gli function has not been determined, although 
GANT61 appears to attenuate the DNA-binding activity of 
Gli1 in vivo and it has been suggested that arcyriaflavin C and 
physalin F indirectly antagonize Gli function through protein 
kinase C/mitogen-activated protein kinase pathway blockade. 
Similarly, the natural product forskolin can nonselectively 
inhibit Hh signaling by activating adenylate cyclase and 
consequently protein kinase A.
The study of these inhibitors has been limited to 
preclinical models, and clinical trials are not currently under 
way. Recently it was shown that GANT61 causes apoptosis 
in myeloid leukemia cells and is able to synergize with 
rapamycin,108 and this raises hopes for further development 
of this type of antitumor drug.
Regulation of Gli acetylation
Another potential approach could be the use of negative 
regulators of histone deacetylase, which would maintain 
Gli acetylation and inhibit its transcriptional activity, as 
demonstrated by pharmacological inhibition with trichostatin 
A or overexpression of the KCASH family of genes, which 
drive histone deacetylase ubiquitination, targeting it for 
proteasomal degradation.37,109
Retinoids: anticancer drugs  
with a hint of the Hh pathway?
Retinoids have an important physiological role in the 
regulation of phenomena such as differentiation and 
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proliferation, both during development and in adult life.110–112 
Experimental evidence exists that retinoids have antitumoral 
action, as in the case of acute promyelocytic leukemia, 
neuroblastoma, and other diseases.113,114
Several retinoids such as acitretin (NCT00020956)115,116 
and tretinoin (NCT00007631)117 or tazarotene (see below) 
have been tested on BCC, either in the form of topical 
cream or systemic therapies and both as treatment and 
chemopreventive therapies. Tazarotene was the first retinoid 
to arouse some interest as a potential drug for the treatment 
of BCC.118–120 In clinical settings, tazarotene use is approved 
for the treatment of psoriasis and acne and is well tolerated 
in patients undergoing an oral or topical regimen.119,121
In 2004, it was demonstrated (on Ptch1+/- mice exposed 
to ultraviolet or ionizing radiation) that tazarotene inhibited 
the formation of new microscopic lesions and reduced BCC 
size.122 In the same year, Bianchi et al presented positive 
results of an experimental administration of tazarotene 
locally to BCC patients (gel 0.1%) once a day for 24 weeks. 
At the end of the study, 70% of lesions showed response to 
treatment and about 30% healed with no disease recurrence 
in 3 years of follow-up.119
There are currently two Phase II clinical trials in patients 
with BCNS (NCT00783965; NCT00489086) with the 
purpose of evaluating the preventive effect of this highly 
tolerable topical drug on BCC formation.
The antitumor effects of retinoids are elicited mainly 
by inducing apoptosis and differentiation, although the 
mechanisms have not been fully assessed. It is not clear if and 
how tazarotene or other retinoids may act on the Hh pathway, 
although a link has been suggested by Goyette et al.123
Whether Hh and retinoids crosstalk or not needs to be 
further verified, but combined therapies with Hh inhibitors 
may provide a useful and promising tool, given their relative 
tolerability.
Overcoming resistance to Hh/Smo 
inhibitors: phosphatidylinositol 
3-kinase and epidermal growth 
factor receptor inhibition
Experimental evidence points to the potential acquisition of 
tumor resistance to Smo antagonist treatment, both by Smo 
receptor mutations or by amplification of Hh pathway down-
stream target genes such as CCND1 and Gli2.66,85,124
Recently a few studies have shown the possibility of 
overcoming drug resistance through the use of inhibi-
tors of other pathways, which are able to interplay or act 
in synergy with Hh to promote tumorigenesis or tumor 
proliferation:
–	 Researchers at Novartis have shown that mechanisms 
of LDE225 resistance can be overcome by the use of 
inhibitors of phosphatidylinositol 3-kinase.66 Importantly, 
this information has been confirmed by another group on 
vismodegib-resistant tumors.85
–	 Another pathway which may cooperate with Hh in BCC 
is epidermal growth factor receptor signaling.125,126 
Recent data in vitro in human cell lines and in vivo in 
mouse models suggest the relevance of targeting this 
cooperation as a new therapeutic hypothesis to be further 
developed.126
Conclusion and future directions
The identification of the Hh pathway as a strategic target 
for BCC treatment has prompted the search of Hh inhibitors 
for therapeutic purposes. Relatively quickly a first molecule 
has been recently approved for clinical use by the FDA, 
and other molecules are undergoing clinical trials. Several 
drugs already approved for other therapies have also been 
tested and proven to be capable of suppressing Hh activity 
(Figure 1). At the moment, most of the molecules that have 
shown therapeutic efficacy target the Smo intramembrane 
receptor, either in its function or in its capacity to migrate 
into the cilium, indicating Smo as a critical component 
of the pathway. Unfortunately, the possibility of BCC 
developing resistance to Smo-targeting drugs (and in general 
to drugs targeting a single structure) is evident, and there have 
already been published papers documenting both mutations 
of the receptor or constitutive activation of the Hh pathway 
downstream of Smo. For this reason, other drugs which target 
other structures of the Smo receptor, or even better with 
different downstream targets in the Hh pathway (including 
GANTs), need to be developed.
One of the reasons for which it is so strategic to suppress 
the Hh pathway in BCC is not only the specific role of 
Hh on initiation and promotion in this type of tumor, but 
also the increasing evidence of the role of the Hh pathway 
in the maintenance of the stem cell and cancer stem cell 
compartments.127,128 Targeting Hh could reduce the pool of 
cancer stem cells remaining after chemotherapy and in this 
way reduce tumor recurrence.
Furthermore, since Hh is not the only mechanism involved 
in tumor formation and maintenance, the use of combinatorial 
treatment is recommended to increase efficiency of the cure.
Another issue to be dealt with is the molecular 
characterization of the patient’s BCC, to avoid unnecessary 
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delay in the identification of the best therapeutic approach 
(ie, do not use target Smo if Smo is mutated). Molecular 
characterization may be very expensive and in order to reduce 
the costs it is also necessary to work on the identification of 
a few discriminating target molecules to be analyzed.
In summary, the approval of vismodegib has provided 
a new and important tool for BCC treatment, but further 
efforts will be needed to find alternative drugs for resistant 
tumors and may be a more economical solution (considering 
the potential cost of vismodegib is currently about USD7500 
per month and the world market is evaluated at at least 
USD1-4 billion per year).56 Although competition, which 
was strong until FDA’s approval of vismodegib, may fade 
in the future, a substantial number of clinical trials are 
currently ongoing and there is a good chance that other useful 
therapeutic instruments will be available shortly.
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